BSD REPORTS FINANCIAL RESULTS 2nd Qtr FISCAL 2013.
Total revenues of $1.5 million for the six months ended February 28, 2013 compared to total revenues of $0.9 million for the same period a year ago
Total revenues of $0.8 million for the second quarter ended February 28, 2013 compared to total revenues of $0.3 million of the second quarter of last year
Total Hyperthermia backlog of approximately $0.8 million
Net loss of $1.9 million for the three months ended February 28, 2013 compared to a net loss of $2.1 million for the three months ended February 29, 2012
Net cash used in operating activities was $1.4 million for the three months ended February 28, 2013 and $3.4 million for the six months ended February 28, 2013
Cash and cash equivalents of $7.7 million
Total stockholders' equity of $11.0 million
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD's product lines include both hyperthermia and ablation treatment systems. BSD's hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other
therapies such as radiation therapy. BSD's microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue.
For more information visit www.BSDMedical.com or call 801-972-5555.
|Printer friendly Cite/link Email Feedback|
|Publication:||Biotech Financial Reports|
|Article Type:||Financial report|
|Date:||May 1, 2013|
|Previous Article:||Synthetic Biologics Sells Clinical Reference Lab.|
|Next Article:||IHS REPORTS SOFT GROWTH IN 2012 MEMS MARKET.|